Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemiaCatherine C. Smith, Neil P. Shah, Qi Wang et al.|Nature|2012Cited by 745
Structure of the Kinase Domain of an Imatinib-Resistant Abl Mutant in Complex with the Aurora Kinase Inhibitor VX-680Matthew A. Young, John Kuriyan, Neil P. Shah et al.|Cancer Research|2006Cited by 277
Crenolanib is a selective type I pan-FLT3 inhibitorCatherine C. Smith, Neil P. Shah, Elisabeth A. Lasater et al.|Proceedings of the National Academy of Sciences|2014Cited by 211
Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase ConformationsMarkus A. Seeliger, Dustin J. Maly, Pratistha Ranjitkar et al.|Cancer Research|2009Cited by 149
CML and the WHO: Why?Ellin Berman, Brian Druker, Sanjay Mohan et al.|Journal of Clinical Oncology|2023Cited by 14